Wysock 26
1995
|
Undisclosed
|
41
|
Mixed ARF (CAP 39.0%, CPE 34.1%)
|
63
|
207
|
35
|
43
|
noninvasive ventilation (N = 21)
|
face mask, pressure support
|
standard oxygen (N = 20)
|
ICU mortality, intubation
|
Antolnelli 27
1998
|
Undisclosed
|
64
|
Mixed ARF (CPO 19%, atelectasis 25%)
|
54
|
120
|
39
|
40
|
noninvasive ventilation (N = 32)
|
face mask, pressure support
|
Invasive ventilation, tidal volume 10 ml/kg (N = 32)
|
Hospital mortality
|
Confalonieri 28
1999
|
Undisclosed
|
56
|
CAP
|
64
|
175
|
37
|
49
|
noninvasive ventilation (N = 28)
|
face mask, pressure support
|
standard oxygen (N = 28)
|
2-month mortality, intubation
|
Antonelli 29
2000
|
Undisclosed
|
40
|
Mixed ARF (ARDS 37.5%, atelectasis 25%)
|
67
|
NA
|
NA
|
40
|
noninvasive ventilation (N = 20)
|
face mask, pressure support
|
standard oxygen (N = 20)
|
Hospital mortality, intubation
|
Delcaux 30
2000
|
Vital Signs Inc
|
123
|
Mixed ARF (CAP 54.5%)
|
58a
|
144a
|
33
|
36 a
|
noninvasive ventilation (N = 62)
|
face mask, CPAP
|
standard oxygen (N = 61)
|
Hospital mortality, intubation
|
Martin 31
2000
|
Undisclosed
|
61
|
Mixed ARF (COPD 38%)
|
61
|
199
|
28
|
57
|
noninvasive ventilation (N = 32)
|
nasal mask, CPAP
|
standard oxygen (N = 29)
|
ICU mortality, intubation
|
Hilbert 32
2001
|
Undisclosed
|
52
|
CAP in immunocompromised patients
|
49
|
139
|
36
|
38
|
noninvasive ventilation (N = 26)
|
face mask, pressure support
|
standard oxygen (N = 26)
|
Hospital mortality, intubation
|
Ferrer 33
2003
|
Red GIRA, Red Respira, and Carburos Metalicos SA
|
105
|
Mixed ARF (CAP 32.4%, CPE 28.6%)
|
62
|
103
|
37
|
37
|
noninvasive ventilation (N = 51)
|
face mask, pressure support
|
standard oxygen (N = 54)
|
ICU mortality, intubation
|
Cosentini 34
2010
|
Undisclosed
|
47
|
CAP
|
69
|
248
|
27
|
35
|
noninvasive ventilation (N = 20)
|
helmet, CPAP
|
standard oxygen (N = 27)
|
Hospital mortality, intubation
|
Squadrone 35
2010
|
Regione Piemonte (CEP AN RAN 07) and Ministero dell’Università (PRIN RANI 07)
|
40
|
Mixed ARF in immunocompromised patients
|
49
|
269
|
30
|
36
|
noninvasive ventilation (N = 20)
|
helmet, CPAP
|
standard oxygen (N = 20)
|
Hospital mortality, intubation
|
Wermke 36
2012
|
Undisclosed
|
86
|
CAP in immunocompromised patients
|
52a
|
270
|
NA
|
NA
|
noninvasive ventilation (N = 42)
|
face mask, pressure support
|
standard oxygen (N = 44)
|
100-day mortality, intubation
|
Zhan 37
2012
|
Beijing Municipal Science and Technology Commission Program
|
40
|
ALI (immunocompromised 30%)
|
46
|
230
|
20
|
32
|
noninvasive ventilation (N = 21)
|
face mask, pressure support
|
standard oxygen (N = 19)
|
Hospital mortality, intubation
|
Brambilila 38
2014
|
RCCS Fondazione Ca’Granda, Ospedale Maggiore Policlinico, Milan
|
81
|
CAP (immunocompromised 32%)
|
67
|
141
|
34
|
33
|
noninvasive ventilation (N = 40)
|
helmet, CPAP
|
standard oxygen (N = 41)
|
Hospital mortality, intubation
|
Azevedo 39
2015
|
Undisclosed
|
30
|
CPO (43.3%), CAP (33.3%)
|
67
|
NA
|
NA
|
NA
|
noninvasive ventilation (N = 16)
|
face mask, pressure support
|
high-flow nasal oxygen (N = 14)
|
Intubation
|
Frat 6
2015
|
French Ministry of Health
|
310
|
Mixed ARF (CAP 63.5%)
|
60
|
155
|
33
|
35
|
noninvasive ventilation (N = 110)
|
face mask, pressure support
|
high-flow nasal oxygen (N = 106); standard oxygen (N = 94)
|
90-day mortality, intubation
|
Lamiale 40
2015
|
Fisher & Paykel
|
100
|
Mixed ARF in immunocompromised patients (sepsis related 50%)
|
62
|
114
|
27
|
NA
|
high-flow nasal oxygen (N = 52)
|
-
|
standard oxygen (N = 48)
|
Intubation
|
Lemiale 41
2015
|
Legs Poix (Chancellerie des Universités de Paris) and OUTCOMEREA Study Group
|
374
|
Pneumonia in immunocompromised patients
|
63 a
|
142
|
26
|
NA
|
noninvasive ventilation (N = 191)
|
face mask, pressure support
|
standard oxygen (N = 183)
|
28-day mortality, intubation
|
Jones 42
2016
|
Greenlane Research and Education Fund
|
303
|
Mixed ARF (COPD 23.9%, Pneumonia 23.8%)
|
73
|
NA
|
33
|
NA
|
high-flow nasal oxygen (N = 165)
|
-
|
standard oxygen (N = 138)
|
90-day mortality, intubation
|
Muncharaz 43
2017
|
Undisclosed
|
65
|
Mixed ARF (CAP 63.1%)
|
62 a
|
97
|
36
|
44
|
noninvasive ventilation (N = 34)
|
face mask, pressure support
|
invasive ventilation, tidal volume 8–10 ml/kg (PBW), Ppl < 35 (N = 31)
|
Hospital mortality
|
Azoulay 7
2018
|
French Ministry of Health
|
776
|
Mixed ARF in immunocompromised patients (Pneumonia 53.0%)
|
64
|
132
|
33
|
NA
|
high-flow nasal oxygen (N = 388)
|
-
|
standard oxygen (N = 388)
|
90-day mortality, intubation
|
He 44
2019
|
National Natural Science Foundation of China
|
200
|
CAP
|
55
|
231
|
25
|
34
|
noninvasive ventilation (N = 102)
|
face mask, pressure support
|
standard oxygen (N = 98)
|
Hospital mortality, intubation
|
Andino 45
2020
|
Spanish Ministry of Health, Social Services, and Equality
|
46
|
Mixed ARF (CAP 30%, HAP 26%)
|
60
|
96
|
32
|
34.3
|
high-flow nasal oxygen (N = 24)
|
|
standard oxygen (N = 22)
|
Hospital mortality, intubation
|
Awadallah 46
2021
|
None
|
52
|
ARDS (pulmonary ARDS 50%)
|
52
|
94.5
|
NA
|
33
|
noninvasive ventilation (N = 26)
|
face mask, pressure support
|
invasive ventilation, tidal volume 6-7ml/kg (PBW), Ppl < 30 (N = 26)
|
Hospital mortality
|
Grieco 47
2021
|
2017 Merck Sharp & Dohme SRL award
|
107
|
ARF in COVID-19 patients
|
65 a
|
102 a
|
28 a
|
34 a
|
noninvasive ventilation (N = 54)
|
helmet, pressure support
|
high-flow nasal oxygen (N = 55)
|
60-day mortality, intubation
|
AlptekİnoĞlu Mendİl 48
2021
|
None
|
100
|
Mixed ARF in immunocompromised patients (pneumonia 74%)
|
59 a
|
262a
|
NA
|
30 a
|
high-flow nasal oxygen (N = 51)
|
|
standard oxygen (N = 49)
|
28-day mortality, intubation
|